The N-6 methyladenosine dynamics in STEMI and the effect of IL-6 inhibition - a hypothesis generating sub-study of the ASSAIL-MI trial

• Published in: Frontiers in immunology Vol. 16; p. 1532325
• Main Authors: Dahl, Tuva B., Quiles-Jiménez, Ana, Broch, Kaspar, Anstensrud, Anne Kristine, Gullestad, Lars, Andersen, Geir Ø., Kleveland, Ola, Øgaard, Jonas, Bjerkeli, Vigdis, Rashidi, Azita, Yang, Kuan, Holven, Kirsten B., Aukrust, Pål, Bjørås, Magnar, Huse, Camilla, Halvorsen, Bente
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2025
• Subjects: Adenosine - analogs & derivatives; Adenosine - blood; Adenosine - metabolism; Aged; epitranscriptome; Female; Humans; inflammation; Interleukin-6 - antagonists & inhibitors; Male; Middle Aged; N6-methyladenosine (m6A); RNA methylation; RNA, Messenger - genetics; ST Elevation Myocardial Infarction - blood; ST Elevation Myocardial Infarction - drug therapy; ST Elevation Myocardial Infarction - genetics; ST Elevation Myocardial Infarction - metabolism; STEMI; tocilizumab; STEMI; N6-methyladenosine (m6A); tocilizumab; epitranscriptome; inflammation; RNA methylation

Epitranscriptomics, with m A as the most prevalent in mammals, is a novel treatment target for inflammatory diseases, including cardiovascular diseases. However, little is known about m A RNA-regulation during myocardial infarction (MI). In this explorative sub-study of the ASSAIL-MI trial, we used...